

1. *Kari P.T. Torgerhagen*, Milan, Minnesota; to retain 8.96 percent, for a total of 29.094 percent of the voting shares of Milan Agency, Inc., Milan, Minnesota, and thereby indirectly retain shares of Prairie State Bank, Milan, Minnesota.

Board of Governors of the Federal Reserve System, September 20, 1995.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 95-23922 Filed 9-26-95; 8:45 am]

BILLING CODE 6210-01-F

### **West One Bancorp; Formation of, Acquisition by, or Merger of Bank Holding Companies; and Acquisition of Nonbanking Company**

The company listed in this notice has applied under § 225.14 of the Board's Regulation Y (12 CFR 225.14) for the Board's approval under section 3 of the Bank Holding Company Act (12 U.S.C. 1842) to become a bank holding company or to acquire voting securities of a bank or bank holding company. The listed company has also applied under § 225.23(a)(2) of Regulation Y (12 CFR 225.23(a)(2)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to acquire or control voting securities or assets of a company engaged in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies, or to engage in such an activity. Unless otherwise noted, these activities will be conducted throughout the United States.

The application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a

hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Comments regarding the application must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 20, 1995.

A. Federal Reserve Bank of San Francisco (Kenneth R. Binning, Director, Bank Holding Company) 101 Market Street, San Francisco, California 94105:

1. *U.S. Bancorp*, Portland, Oregon; to acquire 100 percent of the voting shares of West One Bancorp, Boise, Idaho, and thereby indirectly acquire West One Bank, Idaho, Boise, Idaho; West One Bank, Oregon, Portland, Oregon; West One Bank, Oregon, S.B., Hillsboro, Oregon; West One Bank Washington, Seattle, Washington; West One Bank, Utah, Salt Lake City, Utah; and Idaho First Bank, Boise, Idaho.

In connection with this application, U.S. Bancorp also has applied to acquire West One Trust Company, Salt Lake City, Utah, and West One Trust Company, Washington, Seattle, Washington; and thereby engage in trust company services, pursuant to § 225.25(b)(3) of the Board's Regulation Y; West One Life Insurance Company, Phoenix, Arizona; and thereby engage in credit life and disability reinsurance, pursuant to § 225.25(b)(8)(i) of the Board's Regulation Y; West One Financial Services, Inc., Boise, Idaho, and thereby engage in residential and commercial mortgage servicing, pursuant to § 225.25(b)(1)(iii) of the Board's Regulation Y.

In addition to this application, U.S. Bancorp has applied to acquire 19.9 percent of the voting shares of West One Bancorp, and West One Bancorp has applied to acquire 19.9 percent of the voting shares of U.S. Bancorp, Portland, Oregon, and thereby indirectly acquire U.S. National Bank of Oregon, Portland, Oregon; U.S. Bank of Idaho, N.A., Coeur D'Alene, Idaho; U.S. Bank of Nevada, Reno, Nevada; U.S. Bank of Washington N.A., Seattle, Washington; U.S. Bank of California, Sacramento, California; U.S. Bank of Southwest Washington, Vancouver, Washington; U.S. Bank, N.A., Beaverton, Oregon; U.S. Savings Bank of Washington, Bellingham, Washington; and First State Bank of Oregon, Canby, Oregon.

Board of Governors of the Federal Reserve System, September 20, 1995.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 95-23924 Filed 9-26-95; 8:45 am]

BILLING CODE 6210-01-F

### **Whitney Corporation of Iowa, et al.; Notice of Applications to Engage de novo in Permissible Nonbanking Activities**

The companies listed in this notice have filed an application under § 225.23(a)(1) of the Board's Regulation Y (12 CFR 225.23(a)(1)) for the Board's approval under section 4(c)(8) of the Bank Holding Company Act (12 U.S.C. 1843(c)(8)) and § 225.21(a) of Regulation Y (12 CFR 225.21(a)) to commence or to engage *de novo*, either directly or through a subsidiary, in a nonbanking activity that is listed in § 225.25 of Regulation Y as closely related to banking and permissible for bank holding companies. Unless otherwise noted, such activities will be conducted throughout the United States.

Each application is available for immediate inspection at the Federal Reserve Bank indicated. Once the application has been accepted for processing, it will also be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the question whether consummation of the proposal can "reasonably be expected to produce benefits to the public, such as greater convenience, increased competition, or gains in efficiency, that outweigh possible adverse effects, such as undue concentration of resources, decreased or unfair competition, conflicts of interests, or unsound banking practices." Any request for a hearing on this question must be accompanied by a statement of the reasons a written presentation would not suffice in lieu of a hearing, identifying specifically any questions of fact that are in dispute, summarizing the evidence that would be presented at a hearing, and indicating how the party commenting would be aggrieved by approval of the proposal.

Unless otherwise noted, comments regarding the applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 10, 1995.

A. Federal Reserve Bank of Chicago (James A. Bluemle, Vice President) 230 South LaSalle Street, Chicago, Illinois 60690:

1. *Whitney Corporation of Iowa*, Atlantic, Iowa; to engage *de novo* in making and servicing loans through the purchase loan participations from its subsidiary bank, pursuant to § 225.25(b)(1) of the Board's Regulation Y.

B. Federal Reserve Bank of St. Louis (Randall C. Sumner, Vice President) 411 Locust Street, St. Louis, Missouri 63166:

1. *Universal Bancorp*, Bloomfield, Indiana; to engage *de novo* through a

joint venture, Precedent Bloomfield Financial, LLC, Indianapolis, Indiana, in lending and leasing on manufacturing equipment, office equipment, and real estate up to \$500,000, pursuant to § 225.25(b)(1) and (5) of the Board's Regulation Y. The geographic scope for these activities is the State of Indiana.

Board of Governors of the Federal Reserve System, September 20, 1995.

Jennifer J. Johnson,

*Deputy Secretary of the Board.*

[FR Doc. 95-23923 Filed 9-26-95; 8:45 am]

BILLING CODE 6210-01-F

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. 93D-0236]

#### Gender Studies in Product Development, Scientific Issues and Approaches; Notice of a Public Workshop

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing that a public workshop entitled "Gender Studies in Product Development: Scientific Issues and Approaches" is being held on November 6 and 7, 1995. The workshop will focus on issues related to FDA's guideline entitled "Guideline for the Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs." The guideline provides guidance on FDA's expectations regarding inclusion of both genders in drug development.

**DATES:** The public workshop will be held on November 6 and 7, 1995, from 7:30 a.m. to 4 p.m.; an opportunity for public comment is planned on November 6, 1995, from 2:15 p.m. to 3:15 p.m. Interested persons should register by October 23, 1995. Attendance will be limited based on the availability of seating. Submit written notices of participation by October 23, 1995. Time may be limited depending on the number of participants scheduled to speak.

**ADDRESSES:** The public workshop will be held at Doubletree Hotel, 1750 Rockville Pike, Rockville, MD 20852, 301-468-1100. Participants who wish to speak during the public comment session should request time by sending their name, affiliation, address, and phone number to John Sellman, Sociometrics, Inc., 8300 Colesville Rd., suite 550, Silver Spring, MD 20910,

301-608-2151, or FAX 301-608-3542. There is no registration fee, for this workshop. Those persons interested in attending the public workshop should mail their registration to Sociometrics, Inc. (address above). Copies of the transcript of the workshop summary will be available from the Freedom of Information Public Records and Documents Center (HFI-35), 5600 Fishers Lane, Rockville, MD 20057.

**FOR FURTHER INFORMATION CONTACT:** Mary C. Gross, Office of External Affairs (HF-60), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301-827-3364.

**SUPPLEMENTARY INFORMATION:** In the Federal Register of July 22, 1993 (58 FR 39406), FDA published a notice on a guideline entitled "Guideline for the Study and Evaluation on Gender Differences in the Clinical Evaluation of Drugs." The guideline discusses: Inclusion of patients of both genders in drug development; analyses of clinical data by gender; assessment of potential patient differences on the basis of gender, age, race, disease state, organ function, body size, genetic polymorphism and other characteristics that may affect responses to drugs, biologics or medical devices. The workshop will encourage an open scientific exchange in order to raise questions and issues related to the guideline.

Optimal treatment of patients in some instances, may depend on an awareness of the effect of these characteristics so that suitable adjustments may be made in dosage amount and dosage schedules. Questions have arisen, however, regarding the clinical trials that are needed or that can be developed to carry out appropriate gender analysis and detect important clinical differences in gender related responses.

It is expected that by using gender as the model characteristic in this workshop, important information may be derived regarding patient characteristics that affect the safety and efficacy profile of medical products.

Dated: September 19, 1995.

William B. Schultz,

*Deputy Commissioner for Policy.*

[FR Doc. 95-23996 Filed 9-26-95; 8:45 am]

BILLING CODE 4160-01-F

## National Institutes of Health

### National Institute of Environmental Health Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as

amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

*Name of Committee:* Environmental Health Sciences Review Committee.

*Date:* November 16-17, 1995.

*Time:* 8:30 a.m. to Adjournment.

*Place:* National Institute of Environmental Health Sciences, Building 101 Conference Rooms A, B, & C, South Campus, Research Triangle Park, North Carolina.

*Contact Person:* Dr. Ethel Jackson, Scientific Review Administrator, P.O. Box 12233, Research Triangle Park, NC 27709, (919) 541-7826.

*Purpose:* To review and evaluate grant applications.

The meeting will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and the discussions could reveal confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Program Nos. 93.113, Biological Response to Environmental Health Hazards; 93.114, Applied Toxicological Research and Testing; 93.115, Biometry and Risk Estimation; 93.894, Research and Manpower Development, National Institutes of Health.)

Dated: September 19, 1995.

Susan K. Feldman,

*Committee Management Officer, NIH.*

[FR Doc. 95-23902 Filed 9-26-95; 8:45 am]

BILLING CODE 4140-01-M

## Division of Research Grants; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Division of Research Grants Special Emphasis Panel (SEP) meetings:

*Purpose/Agenda:* To review individual grant applications.

*Name of SEP:* Chemistry and Related Sciences.

*Date:* October 19, 1995.

*Time:* 1:00 p.m.

*Place:* NIH, Rockledge II, Room 5154, Telephone Conference.

*Contact Person:* Dr. Alec Liacouras, Scientific Review Administrator, 6701 Rockledge Drive, Room 5154, Bethesda, Maryland 20892, (301) 435-1740.

*Name of SEP:* Multidisciplinary Sciences.

*Date:* October 30-November 1, 1995.

*Time:* 8:00 p.m.

*Place:* Oklahoma City, Oklahoma.  
*Contact Person:* Dr. Marjam Behar, Scientific Review Administrator, 6701 Rockledge Drive, Room 5218, Bethesda, Maryland 20892, (301) 435-1180.

*Name of SEP:* Clinical Sciences.

*Date:* October 31, 1995.